Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue , 2016, Pages 29-38

  Brauer, Ruth ^a,b   Douglas, Ian ^a   Garcia Rodriguez, Luis Alberto ^c   Downey, Gerald ^b   Huerta, Consuelo ^d   de Abajo, Francisco ^e   Bate, Andrew ^f   Feudjo Tepie, Maurille ^b   de Groot, Mark C H ^g   Schlienger, Raymond ^h   Reynolds, Robert ⁱ   Smeeth, Liam ^a   Klungel, Olaf ^g   Ruigómez, Ana ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b AMGEN LTD   (United Kingdom)

^c Fundación Centro Español de Investigación Farmacoepidemiológica ^*  (Spain)

^d Division of Pharmacoepidemiology and Pharmacovigilance   (Spain)

^e HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^g UTRECHT UNIVERSITY   (Netherlands)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ PFIZER INC   (United States)

Author keywords

Acute liver injury, antibiotics; BIFAP; Case control study; CPRD; Incidence rate; Pharmacoepidemiology; Primary care databases

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEPHALOSPORIN; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; EUROPE; FEMALE; HUMAN; INCIDENCE; LIFESTYLE; LIVER INJURY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; POISSON DISTRIBUTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SEX; SPAIN; STATISTICAL ANALYSIS; STUDY DESIGN; UNITED KINGDOM; CHEMICAL AND DRUG INDUCED LIVER INJURY; FACTUAL DATABASE; MIDDLE AGED; PRIMARY HEALTH CARE; STATISTICS AND NUMERICAL DATA;

ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHEMICAL AND DRUG INDUCED LIVER INJURY; COHORT STUDIES; DATABASES, FACTUAL; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 84962920193     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3861     Document Type: Article

References (30)

1. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995; 58: 108-117.
2. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44: 1581-1588.
3. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.e4.
4. Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010; 32: 3-13.
5. Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother 2011; 66: 1431-1446.
6. Ibanez L, Perez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37: 592-600.
7. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-455.
8. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 38(Suppl 2): S44-S48.
9. Ferrajolo C, Coloma PM, Verhamme KM, et al. Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. Drug Saf 2014; 37: 99-108.
10. Polson JE. Hepatotoxicity due to antibiotics. Clin Liver Dis 2007; 11: 549-561, vi.
11. Reich CG, Ryan PB, Schuemie MJ. Alternative outcome definitions and their effect on the performance of methods for observational outcome studies. Drug Saf 2013; 36(Suppl 1): S181-S193.
12. Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Desideratum for evidence based epidemiology. Drug Saf 2013; 36(Suppl 1): S5-S14.
13. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80.
14. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther 2007; 32: 483-487.
15. Derby LE, Jick H, Henry DA, Dean AD. Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993; 158: 596-600.
16. PROTECT. Pharmacoepidemiological research on outcomes of therapeutics by a European consortium. Available at: www.imi-protect.eu.
17. CPRD. The clinical practice research datalink. Available at: http://www.cprd.com.
18. BIFAP. A computerized database of medical records of Primary Care in Spain. Available at: http://www.bifap.org/summary.php.
19. Salvador Rosa A, Moreno Perez JC, Sonego D, Garcia Rodriguez LA, de Abajo Iglesias FJ. The BIFAP project: database for pharmaco-epidemiological research in primary care. Aten Primaria 2002; 30: 655-661.
20. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015; 1-10. doi:10.1093/ije/dyv098.
21. ENCePP. http://www.encepp.eu/encepp/studiesDatabase.jsp. 2012
22. Ruigomez A, Brauer R, Rodriguez LA, et al. Ascertainment of acute liver injury in two European primary care databases. Eur J Clin Pharmacol 2014; 70: 1227-1235.
23. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996; 156: 1327-1332.
24. Hussaini SH, O'Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol 2007; 19: 15-20.
25. Abbing-Karahagopian VKX, De Vries F, Van Staa T, Yolanda A, col. e. Bridging differences in findings from observational pharmacoepidemiological studies: the Design and Rationale of Work Package 2 of the PROTECT project. Pharmacoepidemiol Drug Saf 2011; 20: S1-S364.
26. Takahashi Y, Nishida Y, Asai S. Utilization of health care databases for pharmacoepidemiology. Eur J Clin Pharmacol 2012; 68: 123-129.
27. Brauer R, Ruigómez A, Downey G, et al. Prevalence of antibiotic use: a comparison across various European health care data sources. Pharmacoepidemiol Drug Saf 2015; DOI: 10.1002/pds.3831.
28. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 858-868.
29. Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf 2013; 36(Suppl 1): S59-S72.
30. Schuemie MJ, Gini R, Coloma PM, et al. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. Drug Saf 2013; 36(Suppl 1): S159-S169.